This site is intended for
US healthcare professionals only.

The BMS Commitment to Patients

BMS is committed to transforming patients' lives through science and to addressing unmet needs in dermatology.

Our research on the TYK2 pathway is a preeminent example of BMS leading the way with pathbreaking science to help patients prevail over serious immune-related diseases such as psoriasis.


  1. Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11-27. doi: 10.1007/s00281-015-0539-8
  2. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555
  3. Diogo D, Bastarache L, Liao KP, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10(4):e012271. doi: 10.1371/journal.pone/0122271
  4. Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149. doi: 10.1126/scitranslmed.aag1974
  5. Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13(4):561-571. doi: 10.1016/s1074-7613(00)00055-8
  6. Richard AJ, Stephens JM. Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol Metab. 2011;22(8):325-332. doi:10.1016/j.tem.2011.03.007